+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 211 Actively Recruiting clinical trials

S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating how well symphysis fundal height SFH measurements alone compare to SFH combined with point of care ultrasound POC-US measuring fetal abdominal circumference AC for detecting small or large for gestational age infants among low-risk pregnant women after 35 weeks gestation. The study aims to improve prenatal identification of abnormal fetal growth, which is linked to risks for mother and baby. This open-label, randomized trial is investigator-sponsored and focuses on low-risk pregnancies managed by midwives. Participants are randomly assigned to one of two groups one group will have fetal growth monitored using SFH measurements alone, while the other will have SFH plus POC-US to measure fetal AC and assess amniotic fluid volume. Measurements occur at scheduled antenatal visits at 35-38, 40, 41, and beyond 41 weeks gestation. If screening suggests abnormal growth or amniotic fluid levels, a formal obstetric ultrasound by a specialist will be performed. All women will have POC-US at 41 and 41 weeks to check amniotic fluid, regardless of group. During the study, midwives will review medical histories, conduct physical measurements, and perform ultrasound assessments following the assigned method. Researchers will compare prenatal screening results to actual birth weights to identify small or large infants. They will also track the number of formal ultrasounds requested, cases of abnormal amniotic fluid, and maternal and neonatal outcomes. Participation lasts from enrollment at 35-38 weeks through delivery and initial postnatal assessment, about one year on average.

Age: 18Years - 45YearsFEMALEPhase Not Applicable
3 locations
P

Actively Recruiting

Researchers are evaluating the diagnostic performance of 68GaBED003 in detecting several types of cancer, including colorectal cancer, gastric cancer, pancreatic ductal adenocarcinoma, invasive lobular breast cancer, and epithelial ovarian cancer. This multi-centre, open-label, single-arm Phase 2 study aims to understand how well this PET imaging agent works in identifying these cancers. Participants receive an injection of 68GaBED003 followed by positron emission tomography PET combined with computed tomography CT imaging during a dedicated visit. The study monitors the diagnostic accuracy of the imaging, assesses tumor uptake of the agent, and evaluates safety and tolerability up to 42 days after injection. The first six participants also help determine optimal imaging timing and dosing. During the study, participants undergo screening, imaging, and safety follow-up, including pregnancy testing for women of childbearing potential. Researchers collect imaging data and monitor for any adverse effects up to 48 hours after injection and continue follow-up assessments for up to 42 days. Overall participation lasts from screening through safety follow-up and post-imaging observation.

Age: 18Years - 79YearsAll GendersPhase 2
6 locations
I

Actively Recruiting

Researchers are creating a national registry in Italy to observe and record how multiple myeloma is diagnosed and treated in routine clinical practice. This observational study aims to describe the standard care for patients with multiple myeloma across different hematology centers, reflecting the current situation and variations in treatment and patient characteristics. Both retrospective and prospective data will be collected to provide a comprehensive view. The study involves a non-interventional, multicenter registry that includes patients diagnosed with multiple myeloma since January 1, 2019. Patients are enrolled consecutively during their routine appointments, and data are collected using an electronic platform. Patients participating in other studies may also be included, with baseline and survival data collected during their participation in interventional trials. Hospital visits for data collection occur approximately every six months. Participants will be followed for up to three years, during which researchers will measure overall survival and time to next treatment. Patient-reported outcomes and costs incurred by patients will also be tracked over this period. The study encourages patient involvement and aims to enhance understanding of multiple myeloma care in Italy without altering standard treatment or requiring additional interventions.

Age: 18Years +All Genders
27 locations
E

Actively Recruiting

Researchers are exploring a new treatment for chronic myeloid leukemia CML, a type of blood cancer. The study aims to evaluate the safety and tolerability of different doses of MK-4208 Tern-701 and to identify the highest dose that participants can tolerate and that may be effective in treating CML. This trial is being conducted in phases 1 and 2 to gather important information about MK-4208s use in this disease. Participants will receive MK-4208 orally at various doses ranging from 160 mg to 500 mg, taken once or twice daily depending on the study part. The study includes multiple groups that receive different doses to compare safety and tolerability. Treatment duration and dosing schedules may vary across the study parts, with careful monitoring of participants during the intervention. Throughout the study, participants will undergo regular assessments including monitoring for dose-limiting toxicities, adverse events, and serious side effects up to three years. Researchers will also track hematologic and molecular responses to the treatment and measure drug levels in the blood over time. Safety, tolerability, and efficacy data will be collected to better understand the potential role of MK-4208 in treating CML, with the study expected to last until 2030 for complete follow-up.

Age: 18Years +All GendersPhase 1Phase 2
54 locations
S

Actively Recruiting

Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.

Age: 18Years +All GendersPhase 3
331 locations
E

Actively Recruiting

Researchers are evaluating the combination of rituximab and golcadomide CC-99282 as a front-line, chemo-free treatment for older frail patients newly diagnosed with Diffuse Large B-Cell Non-Hodgkin Lymphoma DLBCL. This phase II, multicenter study focuses on patients aged 80 years or older who are considered frail based on a simplified geriatric assessment sGA and are not candidates for standard anthracycline-based chemotherapy. The study aims to assess efficacy and safety in this vulnerable population. Participants will receive an induction phase consisting of up to 6 cycles, each lasting 28 days. Cycle 1 includes rituximab intravenously on days 1, 8, and 15, golcadomide orally for days 1 to 14, and dexamethasone orally on days 1, 8, 15, and 22. Cycles 2 through 6 involve rituximab on day 1 and golcadomide orally for days 1 to 14. After induction, patients showing at least a partial response may undergo a consolidation phase starting within 6 to 8 weeks, receiving golcadomide orally for up to 6 more cycles. Involved site radiotherapy is permitted at the end of induction for PET-positive areas and may coincide with consolidation treatment. Throughout the study, patients will undergo response assessments after the 4th and 6th induction cycles and midway through consolidation to evaluate disease progression. Imaging such as PETCT or CT scans will be used for response and sarcopenia assessments. Quality of life will be measured at baseline and at multiple points during and after treatment. Follow-up monitoring will continue for 24 months, with visits every 3 months during the first year and every 6 months during the second year. Patients experiencing disease progression will be followed for survival until study completion. The primary outcome is progression-free survival at 24 months.

Age: 80Years +All GendersPhase 2
20 locations
S

Actively Recruiting

This research is an international multicenter retrospective observational study focusing on patients with Essential Thrombocythemia ET who are positive for the JAK2V617F mutation. It aims to understand the progression from ET to Polycythemia Vera PV and compare clinical outcomes between those who progressed and those who did not, using criteria defined by the International consensus classification of myeloid neoplasms and acute leukemias from 2022. The study consists of two parts a nested case-control study and a comparative retrospective cohort study. The first part compares ET patients who progressed to PV with matched ET patients who did not progress, based on diagnosis year, age at diagnosis, and disease duration. The second part compares patients diagnosed with de novo PV without prior ET to the ET-to-PV cases, again matched by diagnosis year, age, and disease duration. All patients included in the study were diagnosed by the end of 2020 to allow at least 5 years of follow-up. Participants will have their medical histories reviewed retrospectively to analyze clinical data up to the baseline and at the time of progression. Researchers will assess phenotypic changes and clinical outcomes between groups, with no new treatments or interventions administered. The study is observational and aims to gather information from existing records to better understand disease evolution over time.

Age: 18Years - 100YearsAll Genders
24 locations
L

Actively Recruiting

Primary immune thrombocytopenia ITP is a condition where the immune system mistakenly destroys platelets, leading to a low platelet count that increases the risk of bruising and bleeding. This Phase 3 study aims to evaluate the long-term safety, tolerability, and effectiveness of mezagitamab, a subcutaneous injection, in adults with chronic primary ITP. It also studies how the body processes mezagitamab over an extended period. Eligible participants who completed previous mezagitamab studies TAK-079-3002 or TAK-079-1004 may join this continuation trial. Those from TAK-079-1004 must have shown a platelet response previously. Participants receive mezagitamab treatment on demand based on defined dosing criteria and the clinical judgment of the investigator, with treatment courses possibly repeated as needed. During the trial, participants visit the study clinic multiple times for assessments including monitoring treatment-emergent adverse events, platelet response duration, use of rescue therapy, and drug levels in the blood. The study lasts up to about 108 weeks, with evaluations of safety, effectiveness, immunogenicity, and dosing patterns throughout this period.

Age: 18Years +All GendersPhase 3
118 locations
C

Actively Recruiting

Researchers are evaluating the efficacy and safety of rilvegostomig compared to pembrolizumab, both combined with platinum-based doublet chemotherapy, as a first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors express PD-L1 at 1% or higher. This Phase III, randomized, double-blind, global study focuses on patients without certain genetic mutations who have advanced disease not suitable for curative treatment. The trial aims to provide new treatment options for this patient group by comparing two immunotherapy approaches combined with chemotherapy. Participants receive either rilvegostomig or pembrolizumab, each given intravenously on Day 1 of every 21-day cycle, alongside platinum-based doublet chemotherapy carboplatin or cisplatin for up to four cycles. After chemotherapy, patients continue with maintenance monotherapy of their assigned immunotherapy rilvegostomig or pembrolizumab plus pemetrexed given intravenously on Day 1 of each 21-day cycle. This treatment continues until disease progression or unacceptable toxicity. Throughout the study, participants undergo regular assessments including tumor measurements by CT or MRI scans, organ and bone marrow function tests, and monitoring for side effects. Researchers will measure overall survival and progression-free survival for up to approximately six years. Patient-reported outcomes on physical functioning, quality of life, and lung cancer symptoms are also collected. Safety and pharmacokinetics of rilvegostomig are monitored to understand treatment effects and tolerability over the long term.

Age: 18Years +All GendersPhase 3
301 locations
G

Actively Recruiting

Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.

Age: 18Years +All GendersPhase 3
333 locations

1-10 of 211

1